At the news
? BULLISHIMPACT 5/10 8-K filed Jun 12, 2026 at 07:10 ET
Rocket Pharmaceuticals completed the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for $180 million in gross proceeds, a previously announced transaction. The non-dilutive capital infusion boosts pro-forma cash to approximately $322.6 million and extends the company's cash runway into the second quarter of 2028, strengthening its balance sheet as it advances its cardiovascular gene therapy pipeline.
- Completed sale of PRV for $180.0 million in gross proceeds
- Pro-forma cash, cash equivalents and investments increased to approximately $322.6 million
- Cash runway extended into Q2 2028
- Transaction closed on June 10, 2026, announced via press release on June 12, 2026
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access